| Dr Nicholas Alan Johnson, DC | |
|
1710 W 1st St, Ankeny, IA 50023-2526 | |
| (515) 964-3000 | |
| Not Available |
| Full Name | Dr Nicholas Alan Johnson |
|---|---|
| Gender | Male |
| Speciality | Chiropractic |
| Experience | 4 Years |
| Location | 1710 W 1st St, Ankeny, Iowa |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104438357 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 111N00000X | Chiropractor | 105317 (Iowa) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Iowa Chiropractic Clinic | 3173699899 | 4 |
News Archive
Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a medical device company specializing in the treatment of wounds and skin defects, today announced it has received CE Mark authorization to market in Europe that will allow it to define and target its autologous cell suspension technology for particular clinical market segments.
An emerging discipline of noninvasive cardiac imaging, molecular imaging, has evolved constantly in the last few years and is increasingly being translated from the preclinical to the clinical level.
As many as 350,000 Canadians could be suffering with hepatitis C, many of whom are unaware that they are infected, thus continuing to spread the virus. Although there is a vaccine to prevent the spread of the hepatitis A and hepatitis B viruses, there is no vaccine for hepatitis C. The good news is that with new treatments, hepatitis C is now a curable disease.
ETEX Corporation, an advanced biomaterials company, announced today that the FDA has granted 510(k) clearance of CarriGen® Porous Bone Substitute Material. CarriGen is available for immediate sale through ETEX's independent sales force. CarriGen builds upon the clinically proven benefit of ETEX nanocrystalline calcium phosphate technology by adding the advantage of increased porosity and pore size. CarriGen is the first highly porous bone graft substitute that sets hard upon implantation for a complete defect fill.
The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) announce today the identification of three chemical series targeting the treatment of deadly neglected tropical diseases (NTDs), through DNDi's screening of MMV's open access Malaria Box.
› Verified 6 days ago
| Provider Name | Iowa Chiropractic Clinic |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1003960493 PECOS PAC ID: 3173699899 Enrollment ID: O20080904000066 |
News Archive
Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a medical device company specializing in the treatment of wounds and skin defects, today announced it has received CE Mark authorization to market in Europe that will allow it to define and target its autologous cell suspension technology for particular clinical market segments.
An emerging discipline of noninvasive cardiac imaging, molecular imaging, has evolved constantly in the last few years and is increasingly being translated from the preclinical to the clinical level.
As many as 350,000 Canadians could be suffering with hepatitis C, many of whom are unaware that they are infected, thus continuing to spread the virus. Although there is a vaccine to prevent the spread of the hepatitis A and hepatitis B viruses, there is no vaccine for hepatitis C. The good news is that with new treatments, hepatitis C is now a curable disease.
ETEX Corporation, an advanced biomaterials company, announced today that the FDA has granted 510(k) clearance of CarriGen® Porous Bone Substitute Material. CarriGen is available for immediate sale through ETEX's independent sales force. CarriGen builds upon the clinically proven benefit of ETEX nanocrystalline calcium phosphate technology by adding the advantage of increased porosity and pore size. CarriGen is the first highly porous bone graft substitute that sets hard upon implantation for a complete defect fill.
The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) announce today the identification of three chemical series targeting the treatment of deadly neglected tropical diseases (NTDs), through DNDi's screening of MMV's open access Malaria Box.
› Verified 6 days ago
| Provider Name | Iowa Chiropractic Of Grimes Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1124691266 PECOS PAC ID: 3577967512 Enrollment ID: O20210812001688 |
News Archive
Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a medical device company specializing in the treatment of wounds and skin defects, today announced it has received CE Mark authorization to market in Europe that will allow it to define and target its autologous cell suspension technology for particular clinical market segments.
An emerging discipline of noninvasive cardiac imaging, molecular imaging, has evolved constantly in the last few years and is increasingly being translated from the preclinical to the clinical level.
As many as 350,000 Canadians could be suffering with hepatitis C, many of whom are unaware that they are infected, thus continuing to spread the virus. Although there is a vaccine to prevent the spread of the hepatitis A and hepatitis B viruses, there is no vaccine for hepatitis C. The good news is that with new treatments, hepatitis C is now a curable disease.
ETEX Corporation, an advanced biomaterials company, announced today that the FDA has granted 510(k) clearance of CarriGen® Porous Bone Substitute Material. CarriGen is available for immediate sale through ETEX's independent sales force. CarriGen builds upon the clinically proven benefit of ETEX nanocrystalline calcium phosphate technology by adding the advantage of increased porosity and pore size. CarriGen is the first highly porous bone graft substitute that sets hard upon implantation for a complete defect fill.
The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) announce today the identification of three chemical series targeting the treatment of deadly neglected tropical diseases (NTDs), through DNDi's screening of MMV's open access Malaria Box.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Nicholas Alan Johnson, DC 205 Ne 44th St Apt 112, Ankeny, IA 50021-4959 Ph: (406) 890-1637 | Dr Nicholas Alan Johnson, DC 1710 W 1st St, Ankeny, IA 50023-2526 Ph: (515) 964-3000 |
News Archive
Avita Medical Ltd. (ASX: AVH), (OTCQX: AVMXY), a medical device company specializing in the treatment of wounds and skin defects, today announced it has received CE Mark authorization to market in Europe that will allow it to define and target its autologous cell suspension technology for particular clinical market segments.
An emerging discipline of noninvasive cardiac imaging, molecular imaging, has evolved constantly in the last few years and is increasingly being translated from the preclinical to the clinical level.
As many as 350,000 Canadians could be suffering with hepatitis C, many of whom are unaware that they are infected, thus continuing to spread the virus. Although there is a vaccine to prevent the spread of the hepatitis A and hepatitis B viruses, there is no vaccine for hepatitis C. The good news is that with new treatments, hepatitis C is now a curable disease.
ETEX Corporation, an advanced biomaterials company, announced today that the FDA has granted 510(k) clearance of CarriGen® Porous Bone Substitute Material. CarriGen is available for immediate sale through ETEX's independent sales force. CarriGen builds upon the clinically proven benefit of ETEX nanocrystalline calcium phosphate technology by adding the advantage of increased porosity and pore size. CarriGen is the first highly porous bone graft substitute that sets hard upon implantation for a complete defect fill.
The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) announce today the identification of three chemical series targeting the treatment of deadly neglected tropical diseases (NTDs), through DNDi's screening of MMV's open access Malaria Box.
› Verified 6 days ago
Iowa Chiropractic Clinic Chiropractor Medicare: Medicare Enrolled Practice Location: 1710 W 1st St, Ankeny, IA 50023 Phone: 515-964-3000 Fax: 515-964-3014 | |
Dr. Scott Ravn Andersen, DC Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 7302 Nw 19th St, Ankeny, IA 50023 Phone: 641-780-9634 | |
Dr. Rachel Ann Curtis, DC Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 213 N Ankeny Blvd Ste 120, Ankeny, IA 50023 Phone: 515-964-7111 | |
Family Matters Chiropractic, Llc Chiropractor Medicare: Medicare Enrolled Practice Location: 1210 Nw 18th St Ste 110, Ankeny, IA 50023 Phone: 515-630-0158 | |
Dr. Kevin J Stapleford, DC Chiropractor Medicare: Accepting Medicare Assignments Practice Location: 629 S Ankeny Blvd, Ankeny, IA 50023 Phone: 515-964-8547 Fax: 515-964-8563 | |
Mr. Brandon Kyle Boston, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 520 Sw 3rd St Suite 1b, Ankeny, IA 50023 Phone: 515-868-0320 | |
Brookfield Family Chiropractic P.c. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 2005 S Ankeny Blvd, Suite 600, Ankeny, IA 50023 Phone: 515-963-3999 Fax: 515-963-9716 |